Introduction {#S1}
============

Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited disorders due to developmental defects or dysfunction of the immune system components ([@B1]). PID patients can potentially be infected by immunizations if they receive live vaccines ([@B2]). Attenuated oral poliovirus vaccine (OPV) immunization has been associated with poliovirus infection in patients with primary antibody deficiencies and combined immunodeficiencies, which can lead to paralysis ([@B3]--[@B5]).

Paralysis is not the only risk of OPV immunizations in PID patients since some vaccinated PID patients may shed vaccine-derived polioviruses (VDPVs) due to a prolonged period of intestinal replication. VDPV variants of OPV serotypes (PV1, PV2, and PV3) show increased nucleotide divergence in the viral protein 1 (VP1) coding region associated with increased neuropathogenicity ([@B6]). Although neonatal screening has begun to expedite the early diagnosis of patients with severe combined immunodeficiencies (SCIDs) and agammaglobulinemia to modify their vaccination program and therapeutic management, these screening tests do not diagnose T or B cell dysfunction, nor have they been implemented worldwide. On the other hand, approximately 150 countries still use OPV in the national childhood immunization schedule, which can spread and be transmitted to PID patients incidentally. Approximately 100 VDPV infections have been reported in PID patients worldwide to date ([@B4], [@B7], [@B8]). As a potential reservoir for neurovirulent VDPV strains, infected PID patients represent a global risk to unimmunized contacts and to the Global Polio Eradication Initiative ([@B4], [@B9]).

The significant impact of OPV on the elimination of poliomyelitis due to wild poliovirus (WPV) and its additional beneficial properties (e.g., economic costs, easy administration, and superior mucosal antibody response) are evident. However, because WPV type 2 has been eradicated and 90% of circulating VDPV, and approximately 40% of VAPP cases are caused by type 2, type 2 was removed from OPV in all countries globally in April 2016. As a result, screening for immunodeficiency-associated VDPV (iVDPV) shedding of known PID patients is more critical to completing elimination of live type 2 poliovirus from the world ([@B10], [@B11]).

Thus, assessing the risk associated with prolonged iVDPV excretion among PID patients by estimating the prevalence in a worldwide study is of critical importance for stakeholders and decision-makers to build an effective strategy for the polio endgame, including development of potential treatments such as antivirals. Based on several reports showing that not only patients with primary antibody deficiencies but also combined immunodeficiencies are very susceptible to persistent polio and non-polio enterovirus (NPEV) infections ([@B4], [@B12]), this multicenter study has been designed to determine the prevalence of iVDPV in patients with both types of immunodeficiencies and characterize the genetic properties of associated virus strains.

Materials and Methods {#S2}
=====================

Patients {#S2-1}
--------

All patients enrolled in this study were diagnosed with PID from 19 Jeffrey Modell Foundation (JMF) sites in 13 OPV-using countries from January 2014 to November 2015 (Table [1](#T1){ref-type="table"}). Inclusion criteria encompassed patients 6 weeks of age or greater and having a diagnosis of SCID, combined immunodeficiency, agammaglobulinemia, or common variable immunodeficiency (CVID). Other types of PID patients were not included in this study.

###### 

19 Jeffrey Modell Foundation sites from 13 countries enrolled PID patients.

  Country[^a^](#tfn1){ref-type="table-fn"}   City           Site no.[^b^](#tfn2){ref-type="table-fn"}   Enrolled patients   Culture results                                    National polio vaccination[^c^](#tfn3){ref-type="table-fn"}   PID screening
  ------------------------------------------ -------------- ------------------------------------------- ------------------- -------------------------------------------------- ------------------------------------------------------------- ---------------
  India                                      Chandigarh     Site 30                                     23                  23                                                 5 OPV doses (birth-6w-10w-14w-16m)                            No
                                                                                                                                                                                                                                             
  Tunisia                                    Tunis          Site 12                                     40                  40                                                 1 IPV dose (6m)                                               No
  7 OPV doses (2m-3m-6m-18m-6y-12y-18y)                                                                                                                                                                                                      
                                                                                                                                                                                                                                             
  China                                      Shanghai       Site 23                                     52                  51                                                 4 OPV doses (2m-3m-4m-4y)                                     No
  Hong Kong                                  Site 21        11                                          11                  6 OPV doses before 2007 (birth-3m-5m-18m-6y-11y)   No                                                            
                                                                                                                                                                                                                                             
  Colombia                                   Medellin       Site 24                                     25                  25                                                 5 OPV doses (2m-4m-6m-18m-5y)                                 No
                                                                                                                                                                                                                                             
  Iran                                       Tehran         Site 14                                     102                 102                                                6 OPV doses (birth-2m-4m-6m-18m-6y)                           No
                                                                                                                                                                                                                                             
  Mexico                                     Mexico City    Site 25                                     20                  20                                                 2 OPV doses (\>6m-\<5y)                                       No
                                                                                                                                                                                                                                             
  Poland                                     Warsaw         Site 17                                     29                  29                                                 3 IPV doses (3m-5m-16m)                                       No
  1 OPV dose (6y)                                                                                                                                                                                                                            
                                                                                                                                                                                                                                             
  Russia                                     Moscow         Site 18                                     35                  35                                                 2 IPV doses (3m-4.5m)                                         No
  4 OPV doses (6m-18m-20m-14y)                                                                                                                                                                                                               
  Moscow                                     Site 28        20                                          20                                                                                                                                   
  Yekaterinburg                              Site 19        28                                          28                                                                                                                                   
                                                                                                                                                                                                                                             
  Turkey                                     Ankara         Site 27                                     30                  29                                                 2 IPV doses (2m-4m)                                           No
  2 OPV doses (6m-18m)                                                                                                                                                                                                                       
  Ankara                                     Site 26        43                                          43                                                                                                                                   
  Izmir                                      Site 11        75                                          75                                                                                                                                   
  Istanbul                                   Site 20        24                                          24                                                                                                                                   
                                                                                                                                                                                                                                             
  Israel                                     Tel Hashomer   Site 29                                     24                  24                                                 2 OPV doses (6m-18m)                                          No
                                                                                                                                                                                                                                             
  Japan                                      Tokyo          Site 13                                     9                   8                                                  2 OPV doses before 2012 (3m-18m)                              No

*OPV, oral poliovirus vaccine; IPV, inactivated polio vaccine; PID, primary immunodeficiency; w, weeks; m, months; y, years*.

*^a^Countries are organized in order of World Bank income classification (lower middle, upper middle, and upper income)*.

*^b^Site numbers are provided to correspond with subject numbers in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}*.

*^c^WHO vaccine-preventable diseases: monitoring system. 2016 Global summary*.

Assessment of each patient at the different JMF sites met the updated criteria introduced by the European Society for Immunodeficiencies[^1^](#fn1){ref-type="fn"} ([@B13]) and/or the American Academy of Allergy, Asthma & Immunology for the diagnosis of PID ([@B14]). In all studied cases, other defined secondary causes of immunodeficiency were excluded. Other types of PID patients were not included in this study. The standard criteria for diagnosis of patients were summarized in Table S1 in Supplementary Material.

Written informed consent (if 18 years of age or older), assent (if 7--17 years of age) or consent from the parents/guardian (for those less than 7 years) was obtained, in accordance with the principles of the ethics committees or Institutional Review Board of the local institutes using common forms designed by The Task Force for Global Health (TFGH, protocol no: CVE-001, WIRB^®^ Protocol \#20130957; Data Sheet S1 in Supplementary Material) translated to the participant JMF sites' local languages.

Study Design {#S2-2}
------------

Each selected JMF study site identified patients who met the inclusion criteria at the time of enrollment. After collecting consent or assent forms, the JMF study site collected the relevant information to complete the patient's log (to track enrollment and to maintain the link between the unique identifiers) and case report form (CRF), and assigned a coded identification number (ID) under a standardized procedure. IDs, names, and contact information was recorded in the patient's log, which was stored securely at the site until completion of the study. All specimens and CRFs were labeled with ID only and not any personal identifiers. The CRF included region (country based on JMF site), demographic characteristics (including date of birth and gender), clinical features (type of PID, age of onset and medical records including signs or symptoms of poliovirus infection), polio vaccination history (date of first and last OPV exposure and type of exposure), PID treatment modalities, and specimen collection information.

Each JMF study site chose the optimal procedure for collection of two stool samples (about 8 g using provided kits) over a 4-day period depending on the proximity of the patient to the JMF study site, the practicality of patient travel to the study site and the availability of adequate cold storage of the stool sample (Table S2 in Supplementary Material).

After collection, the stool samples were kept refrigerated at a temperature of 2--8°C and shipped to the local or regional Global Polio Laboratory Network (GPLN) laboratory along with supporting documentation. The JMF study site provided an electronic copy of the CRF by encrypted means (using a secure FTP server at TFGH) to Centers for Disease Control and Prevention (CDC) for secure data management. Stool specimens were sent to the GPLN laboratory for isolation of poliovirus and NPEVs. Isolates were sent to the CDC polio/enterovirus laboratory using standard shipping protocols for further characterization and genomic sequencing. GPLN member laboratories in all six WHO regions followed standardized protocols to identify and isolate poliovirus and NPEV. They also differentiated the three poliovirus serotypes, Sabin-like poliovirus, and vaccine derived (VDPV). For VDPVs, they conducted genomic sequencing to determine how long the virus had been circulating or had been excreted in the case of iVDPV excreters. This was done by comparing the nucleotide sequence of the VP1 region of the genome from PV isolates according to published protocols ([@B15], [@B16]). The number of mutations compared to the parent Sabin strain is approximately proportional to the duration of excretion. The accepted definition of an iVDPV is \>1% nucleotide divergence from Sabin types 1 and 3 or \>0.6% for Sabin type 2 in the VP1 coding region ([@B6]).

If testing results were positive for poliovirus or NPEV, the JMF site physician assured that family members were appropriately vaccinated against polio and educated about principles of good hygiene to prevent fecal--oral transmission. The physician also followed-up any patient found to be excreting poliovirus periodically (every 1--2 months) until the cessation of excretion and the procedures for testing and reporting above were followed each time. Patients were considered as having cleared an infection if two consecutive stool specimens in 2 months were negative according to the WHO-recommended surveillance standard of poliomyelitis.[^2^](#fn2){ref-type="fn"}

The TFGH study manager ensured coordination of specimen shipment along with the JMF scientific program director, and laboratory results were communicated to CDC both by the GPLN laboratory through the GPLN global coordinator and by the TFGH study manager and entered into the secure database at CDC.

Statistical Analysis {#S2-3}
--------------------

Statistical analysis was performed using a commercially available software package (SPSS Statistics 17.0.0, SPSS, Chicago, IL, USA). The one-sample Kolmogorov--Smirnov test was applied to estimate whether data distribution is normal. Parametric and non-parametric analyses were performed based on the finding of this evaluation. A *p*-value of 0.05 or less was considered statistically significant.

Results {#S3}
=======

Characteristics of Studied PID Cases and OPV Vaccination {#S3-1}
--------------------------------------------------------

During the study period, a total of 635 patients (444 males and 191 females) were included into this study. CVID was the most common diagnosis of studied patients (*n* = 320) followed by agammaglobulinemia (*n* = 250), SCID (*n* = 54) and combined immunodeficiency \[*n* = 11; all with a diagnosis of major histocompatibility complex (MHC) class II deficiency\]. Age at time of study enrollment was 21.1 ± 15.7 years (mean ± SD) for patients with CVID, 18.0 ± 8.5 years for patients with agammaglobulinemia, 7.9 ± 7.8 years for patients with MHC class II deficiency, and 3.8 ± 4.9 years for SCID patients. None of the patients with SCID or MHC class II deficiency were transplanted prior to the study entry.

Among all enrolled patients from these OPV-using countries, 44 individuals did not receive OPV vaccination based on the prior family history of PID and early diagnosis or modified inactivated polio vaccine-based national childhood immunization schedule (Table [2](#T2){ref-type="table"}). However, the median age at first OPV dose was approximately 2 months (range from birth to 6 years) for the 584 patients who did receive OPV. Past medical history of paralytic disease was identified in 14 patients (1.25% of CVID and 4% of agammaglobulinemia patients), but none of the SCID or MHC class II deficiency cases had a history of paralytic disease. Agammaglobulinemia patients were younger than SCID and CVID patients when they received their last dose of OPV, consistent with the cessation of further OPV doses after an earlier clinical diagnosis of PID (Table [2](#T2){ref-type="table"}).

###### 

Demographic data summary for all 635 PID patients.

  Parameters                                All patients   CVID          Agammaglobulinemia   SCID        MHC class II deficiency
  ----------------------------------------- -------------- ------------- -------------------- ----------- -------------------------
  Number of patients                        635            320           250                  54          11
  Gender (M/F)                              444/191        179/141       237/13               24/30       4/7
  Current age, mean; years (SD)             12.7 (8.2)     21.1 (15.7)   18.0 (8.5)           3.8 (4.9)   7.9 (7.8)
  Age at first OPV dose, mean; years (SD)   0.6 (0.8)      0.5 (1.6)     0.4 (1.2)            1.0 (2.6)   0.6 (0.9)
  Age at last dose, mean; years (SD)        2.3 (2.0)      4.3 (4.9)     3.0 (3.6)            2.2 (3.4)   NA
  Exposure to OPV (Y/N)                     584/51         303/17        233/17               37/17       11/0
  Paralytic disease                         14             4             10                   0           0

*OPV, oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; PID, primary immunodeficiency; MHC, major histocompatibility complex*.

Use of Intravenous and Subcutaneous Immunoglobulin {#S3-2}
--------------------------------------------------

The majority (97%) of enrolled subjects were receiving either intravenous immune globulin (IVIG) or subcutaneous immune globulin (SCIG) while participating in the study. For 19 subjects, no IVIG or SCIG use was noted.

Frequency of Poliovirus and NPEV Isolation {#S3-3}
------------------------------------------

Thirteen patients (2%) excreted poliovirus with most patients excreting for less than 2 months following identification of infection (Table [3](#T3){ref-type="table"}). The median age of poliovirus-excreting patients was 6.5 years (range 3 months--22 years). Patients with combined immunodeficiencies (three SCID and four MHC class II deficiency) were at 10-fold increased risk of excreting poliovirus (10.7%) compared to patients with predominantly antibody defects (1.0%; three CVID and three agammaglobulinemia; *p* \< 0.001). The average age of patients with combined immunodeficiencies excreting poliovirus was significantly lower than in antibody deficient patients (3.3 ± 3.0 vs. 9.2 ± 7.3 years; *p* = 0.044). None of these 13 patients were coinfected with NPEV. Poliovirus excretion was not observed in any of patients with a history of paralytic disease.

###### 

Data summary for all 13 PID patients with isolated poliovirus.

  Patient ID                                Gender   Age at study entry   Diagnosis            Site[^b^](#tfn5){ref-type="table-fn"}   Most recent known OPV exposure   Virus     Excretion duration---no. of nucleotide changes
  ----------------------------------------- -------- -------------------- -------------------- --------------------------------------- -------------------------------- --------- -------------------------------------------------------------
  12-017                                    F        7 years              CVID                 Tunisia                                 6 years                          Sabin 1   1 month---3 nucleotide changes
                                                                                                                                                                                  
  12-007[^a^](#tfn4){ref-type="table-fn"}   M        11 years             MHC II deficiency    Tunisia                                 1 month                          Sabin 2   5 months excretion---9 nucleotide changes (0.9%)
                                                                                                                                                                                  
  12-025                                    F        7 years              MHC II deficiency    Tunisia                                 Unknown                          Sabin 3   1 month---3 mutations
                                                                                                                                                                                  
  14-057                                    M        6 years              Agammaglobulinemia   Iran                                    1 week                           Sabin 2   1 month---no mutations
                                                                                                                                                                                  
  14-108[^a^](#tfn4){ref-type="table-fn"}   F        10 months            MHC II deficiency    Iran                                    6 months                         Sabin 2   10 months excretion on study---12 nucleotide changes (1.2%)
                                                                                                                                                                                  
  14-116[^a^](#tfn4){ref-type="table-fn"}   M        3 months             SCID                 Iran                                    2 months                         Sabin 2   6 nucleotide changes (0.6%)
                                                                                                                                                                                  
  14-117[^a^](#tfn4){ref-type="table-fn"}   F        1 year               SCID                 Iran                                    6 months                         Sabin 2   10 nucleotide changes (1%)
                                                                                                                                                                                  
  26-012                                    M        22 years             CVID                 Ankara, Turkey                          7 years                          Sabin 2   \<3 months---no nucleotide changes
                                                                                                                                                                                  
  27-030                                    F        2.5 years            MHC II deficiency    Ankara, Turkey                          2 years                          Sabin 3   Sequence pending
                                                                                                                                                                                  
  20-003                                    M        8 months             Agammaglobulinemia   Istanbul, Turkey                        6 months                         Sabin 2   5 months excretion on study---3--4 nucleotide changes
                                                                                                                                                                                  
  11-031[^a^](#tfn4){ref-type="table-fn"}   F        11 months            SCID                 Izmir, Turkey                           6 months                         Sabin 3   15 nucleotide changes
                                                                                                                                                                                  
  19-021                                    M        13 years             CVID                 Yekaterinburg, Russia                   5 years                          Sabin 3   No nucleotide changes
                                                                                                                                                                                  
  19-023                                    F        6.5 years            Agammaglobulinemia   Yekaterinburg, Russia                   Not known                        Sabin 2   No nucleotide changes

*OPV, oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; M, male; F, female; PID, primary immunodeficiency; MHC, major histocompatibility complex*.

*^a^Patients with immunodeficiency-associated vaccine-derived polioviruses (iVDPV)*.

*^b^Countries are organized in order of World Bank income classification (lower middle and upper middle income)*.

Non-polio enteroviruses were isolated from 4.7% of evaluated patients (17 CVID, 8 agammaglobulinemia, 2 SCID, and 3 MHC class II deficiency), with a higher prevalence of NPEV infection in MHC class II deficient patients compared to patients with other forms of PIDs (*p* = 0.012; Figure [1](#F1){ref-type="fig"}). There was no difference in NPEV prevalence by gender (5.1% of males and 3.6% of females). Table [4](#T4){ref-type="table"} summarizes the clinical and virologic information for NPEV excreters. Echoviruses were the most commonly isolated virus (41%), followed by coxsackieviruses (24%).

![Prevalence of enterovirus excreters among different groups of primary immunodeficiency patients. C, common variable immunodeficiency; M, major histocompatibility complex II deficiency; A, agammaglobulinemia; S, severe combined immunodeficiencies.](fimmu-08-00685-g001){#F1}

###### 

Data summary for all 30 PID patients with isolated non-polio enteroviruses (NPEVs).

  Patient ID                                Gender   Age at study entry (year)   Diagnosis            Site[^b^](#tfn7){ref-type="table-fn"}   Class of NPEV
  ----------------------------------------- -------- --------------------------- -------------------- --------------------------------------- ----------------------
  12-031                                    M        5                           MHC II deficiency    Tunisia                                 NA
  12-037                                    M        0.4                         MHC II deficiency    Tunisia                                 NA
  12-006[^a^](#tfn6){ref-type="table-fn"}   M        5                           CVID                 Tunisia                                 Negative/E2
                                                                                                                                              
  15-014                                    M        10                          XLA                  Argentina                               E25
  23-003                                    M        7                           Agammaglobulinemia   China                                   NA
  23-004                                    M        14                          Agammaglobulinemia   China                                   NA
  24-020                                    M        22                          CVID                 Columbia                                NA
  24-023                                    M        4                           Agammaglobulinemia   Columbia                                NA
  14-079                                    F        28                          CVID                 Iran                                    EV11
  14-020                                    M        7                           Agammaglobulinemia   Iran                                    EV20
  14-019                                    M        41                          CVID                 Iran                                    EV6
  14-121                                    M        17                          CVID                 Iran                                    NA
  25-020                                    M        8                           CVID                 Mexico                                  NA
  25-019[^a^](#tfn6){ref-type="table-fn"}   M        8                           Agammaglobulinemia   Mexico                                  NA
  27-021                                    F        2                           MHC II deficiency    Ankara, Turkey                          CA5/no second sample
  20-025                                    M        1                           Agammaglobulinemia   Istanbul, Turkey                        EV9
  20-007                                    F        18                          CVID                 Istanbul, Turkey                        CA4
  20-006                                    M        20                          CVID                 Istanbul, Turkey                        EV 33
  11-018                                    M        5                           SCID                 Izmir, Turkey                           CA10
  11-050                                    F        6                           CVID                 Izmir, Turkey                           CA2
  11-048                                    M        0.5                         CVID                 Izmir, Turkey                           CB
  11-042                                    M        11                          CVID                 Izmir, Turkey                           CB4
  11-016                                    M        17                          CVID                 Izmir, Turkey                           E6
  11-075                                    F        0.7                         CVID                 Izmir, Turkey                           NA
  11-068                                    M        7                           CVID                 Izmir, Turkey                           E7
                                                                                                                                              
  29-012                                    F        3                           Agammaglobulinemia   Israel                                  CB5
  29-006                                    F        12                          SCID                 Israel                                  EV01
  29-016                                    M        5                           CVID                 Israel                                  EV11
  29-024                                    M        20                          Agammaglobulinemia   Israel                                  EV13
  29-008                                    M        9                           Agammaglobulinemia   Israel                                  NA

*OPV, Oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; M, male; F, female; CA, coxsackie A virus; CB, coxsackie B virus; EV, enterovirus; E, echovirus; PID, primary immunodeficiency; MHC; major histocompatibility complex*.

*^a^Samples were collected prior to immunoglobulin replacement therapy*.

*^b^Countries are organized in order of World Bank income classification (lower middle, upper middle, and upper income)*.

The mean age of poliovirus excreting patients was significantly lower than NPEV excreters (5.9 ± 4.3 vs. 10.4 ± 9.2 years, *p* = 0.005). Samples from nine patients (1.4% of 635 studied patients) were collected at the time of PID diagnosis and prior to administration of immunoglobulin replacement therapy. Of note, two of these nine cases (22.2%) were NPEV positive, both were diagnosed with antibody deficiency and were from the same center (12-006 and 12-019; *p* = 0.06). No poliovirus was isolated from these nine patients.

Predominance of iVDPV among Combined Immunodeficiency {#S3-4}
-----------------------------------------------------

Five (0.8% of all patients) of 13 poliovirus-excreting patients were considered iVDPV excreters based on the number of VP1 nucleotide changes (median of 10 nucleotide changes; range, 6--15). Of note, all iVDPV excreters had combined immunodeficiency (three SCID and two MHC class II deficiency), and four of these five patients excreted Sabin 2 strains (Table [3](#T3){ref-type="table"}). The median number of mutations did not differ between SCID (1%; range 0.6--1.5%) and MHC II deficiency (1.05%; range, 0.9--1.2%) patients. None of the iVDPV excreters presented with acute flaccid paralysis, but chronic diarrhea was a common clinical manifestation. OPV vaccination had occurred in all of iVDPV excreters, and the median time from the first OPV dose to identification of iVDPV was 10 months (range 3 months--11 years). The sequence divergence suggests that secondary exposure may have been the source of infection in some cases. Further vaccination was avoided in all patients due to the diagnosis of PID.

Clinical Presentation and Genetic Studies of iVDPV Excreters {#S3-5}
------------------------------------------------------------

One MHC class II deficiency patient (12-007) was followed for several years prior to enrollment in the current study showing intermittent VDPV excretion episodes and reinfection with various VDPV strains and with several NPEV from a sibling and from the community ([@B17]). During the current study, he was infected with Sabin 2 strain (Table [3](#T3){ref-type="table"}). The second MHC class II patient (14-108) was a 10-month-old girl with disseminated granulomatous disease (BCGosis) after BCG vaccination at age 4 months who excreted poliovirus for 5 months. The mutation in *CIITA* gene (homozygous c.3242-3244delACA, p.Asn1082del) was confirmed in this patient using targeted PID genes panel sequencing.

The only Sabin serotype-3 iVDPV excreter was a girl with SCID (11-031; *RAG1* c.1682G\>A, p.R561H) enrolled at age 11 months. This poliovirus had the highest number of nucleotide changes (15 nucleotides) observed in the study. Virus elimination was evident 3 months after hematopoietic stem cell transplantation. Two other SCID patients infected by serotype-2 iVDPV had the molecular diagnosis confirmed with a mutation in *ADA* (14-116; homozygous c.415G\>T, p.Glu139X) and a mutation in *RAG1* (14-117; homozygous c.1180C\>T, p.Arg394Trp) genes, respectively.

Discussion {#S4}
==========

Primary immunodeficiency patients having defects in humoral or cellular immunity are at risk of chronic/prolonged infection with enteroviruses, including polioviruses. These patients can excrete iVDPV after receiving OPV or after being exposed to a household or community contact excreting poliovirus. Patients who are excreting polioviruses are at risk of developing paralytic poliomyelitis. Such patients must be identified, and their infection resolved, to protect the patients and achieve global eradication of poliovirus. The present study brings together the JMF network, TFGH, WHO, and CDC to estimate the prevalence of poliovirus excretion in selected PID patients who have been exposed to OPV. Two of the participant countries are high income (Israel and Japan); the remainder are lower (two countries) or upper (seven countries) middle income countries according to the World Bank classification. Three poliovirus excreters were from a lower middle income country (Tunisia), and the remainder were from upper middle income countries. NPEVs were isolated from patients from countries from all three economic strata.

Although few cross-sectional studies have been conducted to identify iVDPV among PID patients without paralysis ([@B12], [@B17]--[@B21]), this study identified the largest number of PID patients both with antibody and combined immune deficiencies. This study also constituted a large number of countries with worldwide distribution from four continents (Asia, Africa, Europe, and South America). Approximately 2% of the studied PID patients excreted poliovirus. PID survival rates are improving in lower and middle income countries ([@B22]). Furthermore, iVDPV excreters are being identified at a markedly increased rate due to improved surveillance that includes polio symptom-free excreters ([@B3]). This reinforces the need for enhanced surveillance of PID patients until polio eradication is certified and the use of OPV is stopped. The findings of this study could help estimate the prevalence of iVDPV excreters, which is needed to assess the global risk to eradication posed by these excreters. Undiagnosed PID patients and cases with delayed diagnosis should be considered as potential contributors to underestimation.

In 5% of the studied patients, NPEV was isolated, and none of them were concomitantly excreting poliovirus. Although this prevalence was lower than in a previously reported single-center study (20%) ([@B12]), it demonstrates the susceptibility of patients with humoral and cellular immunodeficiency to prolonged excretion of all enteroviruses. Higher prevalence of NPEV compared to OPV strains might be due to the multiplicity of circulating NPEV serotypes. Moreover, immunoglobulin preparations used for treatment of PID patients do not contain high titers of immunoglobulin against all NPEVs. Of note, immunoglobulin replacement might contribute to the relatively short-term excretion of OPV strains observed in some PID patients; however, we could not test this phenomenon as all poliovirus excreters in this study were receiving IVIG or SCIG treatment.

Poliovirus 2 was the most prevalent serotype detected in iVDPV excreting PID patients (80%), followed by serotype 3 (20%); consistent with the findings in PID patients with paralysis ([@B4], [@B8]). Concurrent infection with more than one iVDPV serotype has been documented in other studies; but we did not observe simultaneous shedding of more than one iVDPV serotype in any patient. Possible explanations for the predominance of poliovirus 2 include the high frequency of recombination that can occur with poliovirus 1 and 3 in OPV vaccinated individuals, resulting in a virus with a higher replication efficiency ([@B23]--[@B26]). Sabin poliovirus 2 also replicates longer and is transmitted more readily due to greater replication fitness or the ability to out-compete the other two serotypes for the binding to the CD155 receptor in the host cells ([@B27], [@B28]). Although these characteristics are potential factors for an increased risk of iVDPV2 in PID, they contributed to the eradication of WPV type 2 ([@B29]) and poliovirus 2 has since been removed from the trivalent OPV vaccine ([@B30]).

All SCID poliovirus excreters and 50% of MHC class II deficient poliovirus excreters became iVDPV excreters. While the number of iVDPV excreters was small, this result suggests that cellular immunity may contribute effectively to clearance of enterovirus infections including cessation of poliovirus excretion. Both humoral (antigen-specific plasma cells and memory B cells) and cellular (memory T cells) immunities should be developed following an effective immunization especially for complex vaccines against viruses. In addition to the capability of OPV-infected dendritic cells to engage specific CD8 T cells, the presence of OPV-specific CD4 T cells in vaccinated individuals is crucial. CD4 T cells are involved in serotype-specific antibody production (B cell priming by follicular helper T cells) and interferon gamma production to lyse infected target cells (virus clearance by cytolytic effector CD4 cells as well as cytolytic effector CD8 T cells). Antigen presentation in both functions of CD4 T cells is through MHC class II ([@B31]). Therefore, patients with combined immunodeficiencies who lack both humoral and cellular immunities may be more likely to be unable to stop virus excretion. However, the presence of six patients with antibody deficiency with long-term poliovirus shedding (approximately 9 years) highlights the important role of viral specific-antibodies in complete clearance of the virus ([@B32]). Considering the several reports of antibody deficient patients with paralysis caused by iVDPV, the identification and treatment of poliovirus symptom-free virus excreting patients is necessary ([@B3]--[@B5]).

Wild poliovirus or iVDPV infections were not observed in the patients with a history of the paralytic disease, and none of their neurologic symptoms were linked to poliovirus infection. Moreover, paralytic disease in the context of PID has several potential etiologies including neurologic autoimmune disorders including multiple sclerosis, myalgic encephalomyelitis, myasthenia gravis, Guillain--Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and vasculitic neuropathies. Moreover, vitamin deficiency (B12) and paraneoplastic neuropathy should be considered as differential diagnosis for paralysis in PID patients ([@B33]).

This study provides an estimate of the global iVDPV prevalence among PID patients without paralytic disease and supports expanded screening for iVDPV excretion in these patients. Although most previous studies focused on the risk of long-term iVDPV infection in antibody deficient patients, the predominance of risk in patients with combined immunodeficiencies included in the current study highlights the importance of considering this group of PID patients in any surveillance program. Reinfection with poliovirus and NPEV excretion in PID patients described elsewhere demonstrates the need for prolonged follow-up ([@B17]).

The Global Polio Eradication Initiative plans to cease use of OPV worldwide once WPV has been certified as eradicated, which will end the generation of new iVDPVs. However, there is currently no means for addressing the threat posed by existing immunodeficient persons infected with iVDPVs, either to the infected individual's risk of paralytic disease, or to the community of a continuing source of poliovirus transmission. Antivirals represent a potential means to manage the treatment of iVDPV excreters and the risk they present to the eradication effort ([@B32], [@B34]). Two safe virus-specific antivirals acting by differing mechanisms are now being developed and may be used as a combination (e.g., pocapavir and V-7404). This strategy may resolve the individual's infection, stop iVDPV excretion, and serve to eliminate the risk of poliovirus transmission in the community. Currently, pocapavir is being considered for use in poliovirus excreting PID patients on a compassionate use basis.

The limitations of the existing study include that no low-income level country participated, which may bias the generalization of these findings. Moreover, other forms of less profound combined immunodeficiency should be evaluated in future studies since this study recruited only patients with MHC class II deficiency.

The potential risk posed by iVDPV excreters to the polio eradication effort indicates the immediate need to develop and implement a global iVDPV surveillance strategy. Utilizing this approach, individuals at risk of prolonged poliovirus excretion can be identified and antiviral treatment can be initiated.
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